Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

asciminib hydrochloride

(as-KIH-mih-nib HY-droh-KLOR-ide)
A drug used to treat adults with chronic phase chronic myelogenous leukemia that is Philadelphia chromosome positive. It is used in patients whose cancer has the T315I mutation, whose cancer is newly diagnosed, or whose cancer was treated with at least two other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Asciminib hydrochloride blocks the BCR::ABL1 fusion protein, which may help keep cancer cells from growing and may kill them. Asciminib hydrochloride is a type of tyrosine kinase inhibitor. Also called Scemblix.
More Information
Search NCI's Dictionary of Cancer Terms